IGF1 and Modifying Effects on Tumors

OR21-1

Normative Data of the VARIETE Cohort Influences Clinical Interpretation of Total IGF-I Levels Measured By the IDS-iSYS Assay
Aimee J Varewijck, Aart J. van der Lely, Sebastian J.C.M.M. Neggers, Leo J. Hofland and Joseph A M J L Janssen

OR21-2

Serum IGF-I Levels Are Associated with Improved White Matter Recovery and Short Term Memory after Traumatic Brain Injury
Claire Feeney, David Sharp, Peter J Hellyer, James H Cole, Gregory Scott, David Baxter, Sagar Jilka, Euan Ross, Timothy Ham, Mark Midwinter and Anthony P. Goldstone

OR21-4

Increased Incidence of Malignancy in Patients with Non-Functioning Pituitary Adenoma – a Nationwide Study
Daniel S Olsson, Casper Hammarstrand, Ing-Liss Bryngelsson, Anna G Nilsson, Eva Andersson, Gudmundur Johannsson and Oskar Ragnarsson

OR21-6

Role of an Ethnically Disparate p53 Polymorphism at Codon 72 in Susceptibility to Mammary Tumorigenesis in a Humanized Mouse Model
Ramesh T Gunaratna, Andres Santos, Chandandeep Nagi, Claudio Conti and Robin S L Fuchs-Young